Family: | ProShares |
Name: | ProShares UltraShort Nasdaq Biotechnology |
Inception Date: | 7-Apr-2010 |
Termination Date: | |
Investment Objective: | ProShares UltraShort Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the inverse (opposite) of the daily performance of the NASDAQ Biotechnology Index. |
Prospectus | |
Top 10 Holdings | ||
Derivatives offset | 199.9814% | |
Net Other Assets (Liabilities) | 100.0000% | |
NASDAQ Bio Index SWAP BNP | -69.8290% | |
NASDAQ Biotechnology Index SWAP Societe Generale | -51.7929% | |
NASDAQ Biotechnology Index SWAP Morgan Stanley & Co. International PLC | -28.0291% | |
NASDAQ Biotechnology Index SWAP Citibank NA | -26.5667% | |
NASDAQ Biotechnology Index SWAP UBS AG | -14.9895% | |
NASDAQ Biotechnology Index SWAP Bank of America NA | -8.7743% | |
Top 10 Holdings Weight: | 100.0% |
Number of Holdings: | 8 |
Shares Outstanding: | 171,100 |
Total Net Assets: | 3,411,734 |
NAV: | 19.95 |
Net Expense Ratio: | 0.95% |
Asset Class: | Equities (Stocks) |
Developed or Emerging: | Developed Market Funds |
Country: | US |
Region: | |
Strategy: | |
Currency: | |
Commodity: | |
Sector: | Healthcare |
Industry: | Biotech |
Dividend Type: | |
Tax Exempt State: | |
Maturity Duration: | |
Market Cap: | Broad Market / Multi-Cap |
Credit Quality: | |
Mortgage Bond Types: | |
Bond Type: | |
Gov't Bond Types: | |
Reit Type: | |
Leverage Direction/Factor: | Inverse (-2x) |
Is Currency Hedged: | No |
US or Ex-US: | Domestic |